SMZ1 주식 개요 중화인민공화국에서 투자 지주 회사인 Sino Biopharmaceutical Limited는 연구 개발 제약 대기업으로 운영되고 있습니다. 자세한 내용
생각, 링크 및 회사 내러티브를 캡처하세요.
Sino Biopharmaceutical Limited 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 Sino Biopharmaceutical 과거 주가 현재 주가 HK$0.38 52주 최고치 HK$0.48 52주 최저치 HK$0.29 베타 0.68 1개월 변경 -6.15% 3개월 변경 사항 -13.82% 1년 변경 사항 -0.34% 3년 변화 -42.17% 5년 변화 -56.52% IPO 이후 변화 3,715.31%
최근 뉴스 및 업데이트
Sino Biopharmaceutical Limited Announces Positive Results from Phase III Study of Benmelstobart Injection in Combination with Chemotherapy Dec 27
Sino Biopharmaceutical Limited Obtains Permission to Submit Marketing Application for Indication of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for Treatment of Advanced Alveolar Soft Part Sarcoma Dec 19
Sino Biopharmaceutical Limited Announces Positive Results from Phase III Study of Benmelstobart Injection with or Without Anlotinib Hydrochloride Capsules as Consolidation Therapy After Chemoradiotherapy for Non-Small Cell Lung Cancer Dec 18
Sino Biopharmaceutical Limited Announces Approval for Marketing of Eribulin Mesilate Injection Dec 11
Sino Biopharmaceutical Limited Announces Approval for Marketing of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsule for the Indication of Treatment for Endometrial Cancer Nov 27
Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsule in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Carcinoma Nov 21 더 많은 업데이트 보기
Sino Biopharmaceutical Limited Announces Positive Results from Phase III Study of Benmelstobart Injection in Combination with Chemotherapy Dec 27
Sino Biopharmaceutical Limited Obtains Permission to Submit Marketing Application for Indication of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for Treatment of Advanced Alveolar Soft Part Sarcoma Dec 19
Sino Biopharmaceutical Limited Announces Positive Results from Phase III Study of Benmelstobart Injection with or Without Anlotinib Hydrochloride Capsules as Consolidation Therapy After Chemoradiotherapy for Non-Small Cell Lung Cancer Dec 18
Sino Biopharmaceutical Limited Announces Approval for Marketing of Eribulin Mesilate Injection Dec 11
Sino Biopharmaceutical Limited Announces Approval for Marketing of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsule for the Indication of Treatment for Endometrial Cancer Nov 27
Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsule in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Carcinoma Nov 21
Sino Biopharmaceutical Limited Announces Approval for Clinical Trials of the Fourth-Generation EGFR Inhibitor "TQB3002" in the United States Nov 14
Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsules in Combination with Chemotherapy for First-Line Treatment of Advanced Soft Tissue Sarcoma Oct 21
Key Executive recently sold €5.9m worth of stock Oct 06
First half 2024 earnings released: EPS: CN¥0.077 (vs CN¥0.06 in 1H 2023) Sep 27
Sino Biopharmaceutical Limited Announces Phase III Study Results of Culmerciclib in Combination with Fulvestrant for Treatment of HR+/HER2- Advanced Breast Cancer Following Endocrine Treatment Presented At 2024 CSCO Sep 27
Sino Biopharmaceutical Limited Announces Phase III Study Results of Anlotinib Hydrochloride Capsules in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Cancinoma Was Presented at ESMO 2024 Sep 16
Upcoming dividend of HK$0.03 per share Sep 03
Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Anlotinib Hydrochloride Capsule in Combination with Penpulimab for First-Line Treatment of Advanced Hepatocellular Carcoma Aug 28
First half 2024 earnings released: EPS: CN¥0.16 (vs CN¥0.068 in 1H 2023) Aug 14
Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsule for First-Line Treatment of Advanced Renal Cell Carinoma Aug 01
Sino Biopharmaceutical Limited to Report Q2, 2024 Results on Aug 13, 2024 Jul 31
Sino Biopharmaceutical Limited Announces Interim Analysis of Phase III Clinical Trial of the Categroy 1 Innovative Drug Culmerciclib Capsule Jul 18
Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Anlotinib Hydrochloride Capsule in Combination with Chemotherapy for First-Line Treatment of Advanced Soft Tissue Sarcoma Jul 16
Sino Biopharmaceutical Limited Announces Acceptance of New Drug Application for Categroy 1 Innovative Drug Rovadicitinib Tablet Jul 15
Sino Biopharmaceutical Limited Receives Approval for Marketing of Liraglutide Injection Jun 25
Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Innovative Drug Envonalkib Citrate Capsules "Envonalkib (TQ-B3139)" Jun 19 Sino Biopharmaceutical Limited Announces Approval for Marketing of Gadoteridol Injection
Sino Biopharmaceutical Limited Announces Retirement of Ms. Li Mingqin as Executive Director Jun 06
Upcoming dividend of HK$0.03 per share Jun 04
Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for First-Line Treatment of Advanced Renal Cell Carcinoma May 24
Sino Biopharmaceutical Limited Receives Marketing Approval from National Medical Products Administration of China May 10
Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Unecritinib Fumarate Capsules May 01
Full year 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.11 in FY 2022) Apr 30
Executive Chairwoman of the Board recently bought €695k worth of stock Apr 22
Sino Biopharmaceutical Limited, Annual General Meeting, Jun 05, 2024 Mar 29
Full year 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.14 in FY 2022) Mar 28
Sino Biopharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 5 July 2024 Mar 28
Sino Biopharmaceutical Limited Provides Update on Development Progress of Mash Products "Lanifibranor" and "TQA2225" Mar 16
Sino Biopharmaceutical Limited Announces Latest Results of Phase II Clinical Study of KRAS G12C Inhibitor Garsorasib Tablet Mar 13
Sino Biopharmaceutical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024 Mar 02
Sino Biopharmaceutical Limited Announces Acceptance of the New Indication Application for Marketing of Anlotinib Hydrochloride Capsules and Anti Pd-L1 Benmelstobart Feb 28
Qingdao Ocean Innovative Products Investment Fund Co., Ltd. and Qingdao Ocean New Kinetic Energy Products Investment Fund (Limited Partnership) agreed to acquire 67% stake in CP Pharmaceutical (Qingdao) Co., Ltd from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 1.8 billion. Feb 08
Sino Biopharmaceutical Limited Announces Prioritised Evaluation Granted for KRAS G12c Inhibitor Garsorasib Tablet (D-1553) Jan 23
Now 22% undervalued Jan 12
Sino Biopharmaceutical Limited Announces Approval of Clinical Trial for Neuropathic Pain Dec 28
Sino Biopharmaceutical Limited Announces Completion of Patient Enrollment in Phase III Clinical Trial of Anlotinib Combined with Chemotherapy in First-Line Treatment of Advanced Soft Tissue Sarcoma Dec 22
Sino Biopharmaceutical Limited Announces Phase I Clinical Research Results of Tqh2722 Dec 12
Sino Biopharmaceutical Limited Announces First Dose of the First Batch of Subjects in Phase I Clinical Trial of TQA3038 Dec 05
An unknown buyer acquired Suzhou Tianqing Xingwei Med./Lianyungang Chia Tai Tianqing Med./Zhejia Tianqing Zhongwei Med. from Sino Biopharmaceutical Limited (SEHK:1177) for approximately CNY 150 million. Nov 10
Sino Biopharmaceutical Limited Announces Application for Phase Ib/II Clinical Trial of Innovative Drug Oct 17 An unknown buyer acquired 84.2% stake in Shanghai Chia Tai Tongyong Pharmaceutical Co., Ltd. from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 290 million. Oct 11
Upcoming dividend of HK$0.02 per share at 2.7% yield Sep 27
Sino Biopharmaceutical Limited Announces IND Application of Innovative Medicine TRD205 (AT2R Antibody) Filed with and Accept by FDA Sep 26
First half 2023 earnings released: EPS: CN¥0.068 (vs CN¥0.10 in 1H 2022) Aug 27
Sino Biopharmaceutical Limited Announces Interim Cash Dividend for the Period Ended 30 June 2023, Payable on 27 October 2023 Aug 26
New minor risk - Share price stability Aug 20
Sino Biopharmaceutical Limited to Report First Half, 2023 Results on Aug 25, 2023 Aug 03
Key Executive recently bought €4.0m worth of stock Jul 04
Sino Biopharmaceutical Limited Announces Application for Marketing of Loxoprofen Sodium Cataplasms Jul 01
Upcoming dividend of HK$0.06 per share at 3.0% yield Jun 13
Sino Biopharmaceutical Limited Announces New Drug Marketing Application for the Category 1 Innovative Anti-Tumor Medicine May 24
Sino Biopharmaceutical Limited Announces Approval for Marketing by National Medical Products Administration of China for F-627 (Efbemalenograstim alfa Injection) May 11
Executive Vice Chairwoman of the Board recently bought €2.4m worth of stock Apr 06
Full year 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.78 in FY 2021) Apr 02
Sino Biopharmaceutical Limited Announces Clinical Trial Application of Innovative Medicine "Tqb2103 (Claudin18.2 ADC)" Accepted by Center for Drug Evaluation Feb 11
Sino Biopharmaceutical Limited Announces Application for Marketing of Category I Innovative Drug Tqb2450 Injection in Combination with Anlotinib Hydrochloride Capsules for the Indication of First-Line Treatment of Small Cell Lung Cancer Jan 14
Sino Biopharmaceutical Limited Announces the Enrollment of All Patients in Phase III Clinical Trial of "Tqg203" Dec 10
Less than half of directors are independent Nov 16 Sino Biopharmaceutical Limited Provides Revenue Guidance for 2023
Upcoming dividend of HK$0.06 per share Aug 30
First half 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.45 in 1H 2021) Aug 24
Sino Biopharmaceutical Limited Announces Interim Cash Dividend for the period ended 30 June 2022, Payable on 28 September 2022 Aug 24
Sino Biopharmaceutical Limited to Report First Half, 2022 Results on Aug 23, 2022 Aug 12 Sino Biopharmaceutical Limited Announces CEO Changes, Effective July 28, 2022
Sino Biopharmaceutical Limited Announces Application for Marketing of Category 1 Anti-Tumor Innovative Drug TQ-B3101 Capsule Jun 28
Sino Biopharmaceutical Limited Announces Approval of Category 1 Innovative Drug TQC2938 Injection for Clinical Trial Jun 15
Upcoming dividend of HK$0.04 per share Jun 08
Sino Biopharmaceutical Submits Application for Marketing of the Category I Anti-Tumor Innovative Drug "TQ-B3139" May 24
Full year 2021 earnings released: EPS: CN¥0.78 (vs CN¥0.15 in FY 2020) May 01 Sino Biopharmaceutical Limited's Category I Anti-Tumor Innovative Drug "TQB2930" Obtained Approval for Clinical Trial Apr 21
Sino Biopharmaceutical Limited Announces Anlotinib Hydrochloride Capsules Obtains Approval for the Fifth Indication Apr 20
Sino Biopharmaceutical Limited Announces Innovative Drug "TQ-B3525" Was Included in the List of Breakthrough Therapy Drugs by CDE Apr 09
Sino Biopharmaceutical Limited Announces That Application for Clinical Trial of "TQC2938" Injection, A Category I New Drug Self-Developed by the Group, Has Been Submitted to and Accepted by the National Medical Products Administration of China Apr 08
Sino Biopharmaceutical Limited, Annual General Meeting, Jun 06, 2022 Apr 01
Full year 2021 earnings released: EPS: CN¥0.78 (vs CN¥0.15 in FY 2020) Apr 01
Sino Biopharmaceutical Limited Proposes Final Dividend for the Final Dividend for 2021, Payable on 12 July 2022 Apr 01
Sino Biopharmaceutical Limited Announces Category I Anti-Tumour Innovative Medicine FHND5071 Obtained Approval for Clinical Trial Mar 30
Sino Biopharmaceutical Limited to Report Fiscal Year 2021 Results on Mar 31, 2022 Mar 03
Sino Biopharmaceutical Limited Announces Approval of "Adalimumab Solution for Injection" for Marketing Jan 22
Sino Biopharmaceutical Limited Announces Sitagliptin Phosphate and Metformin Hydrochloride Sustained-Release Tablets Obtained Drug Registration Certificate Granted by National Medical Products Administration Jan 12
Sino Biopharmaceutical Limited's TCR1672 Obtains Approval for Clinical Trial Dec 22
Founder & Senior Vice Chairman recently bought €3.2m worth of stock Oct 08
VP & Executive Director recently bought €1.4m worth of stock Sep 22
Founder & Senior Vice Chairman recently bought €11m worth of stock Sep 02
Second quarter 2021 earnings released: EPS CN¥0.35 (vs CN¥0.019 in 2Q 2020) Sep 01
Akeso, Inc. and Sino Biopharmaceutical Limited Announces Penpulimab Monoclonal Antibody Marketing Approval in China Aug 08
Founder & Senior Vice Chairman recently bought €11m worth of stock Jul 28
Sino Biopharmaceutical Limited Announces "Dexmedetomidine Hydrochloride Injection" Obtains Drug Registration Certificate Jul 16 주주 수익률 SMZ1 DE Pharmaceuticals DE 마켓 7D 0.2% 1.2% 1.2% 1Y -0.3% -14.1% 10.1%
전체 주주 수익률 보기
수익률 대 산업: SMZ1 지난 1년 동안 -14.1 %를 반환한 German Pharmaceuticals 산업을 초과했습니다.
수익률 대 시장: SMZ1 지난 1년 동안 10.1 %를 반환한 German 시장보다 저조한 성과를 냈습니다.
가격 변동성 Is SMZ1's price volatile compared to industry and market? SMZ1 volatility SMZ1 Average Weekly Movement 5.7% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
안정적인 주가: SMZ1 지난 3개월 동안 German 시장에 비해 상당한 가격 변동성이 발생하지 않았습니다.
시간에 따른 변동성: SMZ1 의 주간 변동성 ( 6% )은 지난 1년 동안 안정적인 모습을 보였습니다.
회사 소개 투자 지주 회사인 중화인민공화국 바이오제약 유한회사는 중화인민공화국에서 연구 개발 제약 대기업으로 운영되고 있습니다. 이 회사는 세 가지 부문으로 운영됩니다: 현대화된 중국 의약품 및 화학 의약품, 투자 및 기타. 이 회사는 포커스 브이 브랜드의 안로티닙 염산염 캡슐, 애니케 브랜드의 펜풀리맙 주사, 일리슈 브랜드의 에페말레노그라스틴 알파 주사, 애니유 브랜드의 포말리도마이드 캡슐, 안베이시 브랜드의 베바시주맙 주사, 델리투오 브랜드의 리툭시맙 주사, 사이투오 브랜드의 주사제 트라스투주맙 등 종양학 의약품을 공급하고 있습니다; 톈칭 간메이 브랜드의 이소글리시리진산 마그네슘 주사제와 런중 브랜드의 엔테카비르 분산형 정제 등 간 질환 치료제, 톈칭 수양 브랜드의 흡입용 부데소니드 현탁액과 톈윈 브랜드의 주사제 콜리스티메테이트 나트륨으로 구성된 호흡기 의약품을 판매하고 있습니다.
자세히 보기 Sino Biopharmaceutical Limited 기본 사항 요약 Sino Biopharmaceutical 의 수익과 매출은 시가총액과 어떻게 비교하나요? SMZ1 기본 통계 시가총액 €6.77b 수익(TTM ) €283.59m 수익(TTM ) €3.68b
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) SMZ1 손익 계산서(TTM ) 수익 CN¥27.79b 수익 비용 CN¥5.23b 총 이익 CN¥22.56b 기타 비용 CN¥20.41b 수익 CN¥2.14b
주당 순이익(EPS) 0.12 총 마진 81.16% 순이익 마진 7.71% 부채/자본 비율 22.6%
SMZ1 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기 기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2025/01/09 10:56 장 마감 주가 2025/01/09 00:00 수익 2024/06/30 연간 수익 2023/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 Sino Biopharmaceutical Limited 51 애널리스트 중 23 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Justin Liu BNP Paribas Securities (Asia) Ling Zhang BNP Paribas Securities (Asia) Wai Chak Yuen BOCI Research Ltd.
48 더 많은 분석가 보기 
